Septerna, Inc. announced the initiation of a Phase 1 clinical trial for its oral small molecule drug candidate SEP-479, targeting hypoparathyroidism, with initial data expected in late 2026 or early 2027.
Key takeaways
The company dosed the first participants in a Phase 1 trial for SEP-479, a potential oral treatment for hypoparathyroidism.
The trial is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 150 healthy volunteers.
Data from the single-ascending and multiple-ascending dose study is anticipated in late 2026 or early 2027.
The company also updated its corporate presentation for use in investor meetings on the same date.